On November 9, 2020 Cygnal Therapeutics, the first company to build a platform to develop drugs in the new field of exoneural biology, reported that it will present a poster this week at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 35th Anniversary Annual Meeting (Press release, Cygnal Therapeutics, NOV 9, 2020, View Source [SID1234570664]). The conference will be held online as a virtual event . Cygnal’s poster will discuss research on the development and use of novel monoclonal antibodies to block tumor-promoting interactions with Neuropilin-1, leading to significant tumor growth inhibition in vivo.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: A novel mechanism of Neuropilin-1 inhibition results in improved tumor growth inhibition in vivo
Number: 683
Presenters: Daniel Blom, Ph.D., Shalini Sethumadhavan, Ph.D., Eric Zhu, Ph.D.
Date and Time: Available virtually on Monday, November 9 from 8:00 a.m. ET onward
Registered event attendees can access the poster via their SITC (Free SITC Whitepaper) event login. Cygnal’s poster presenters will be available for questions online on Wednesday, November 11 from 5:15 to 5:45 p.m. ET and on Friday, November 13 from 4:40 to 5:10 p.m. ET.
To learn more about Cygnal and exoneural biology, please visit Cygnal’s website.